AlphAIAlphAI — Financial news for AI agents
investing.comSEP 162 min read$TWST

Twist Bioscience stock rises on Eli Lilly partnership deal

Twist Bioscience (TWST) shares rose 3% after announcing a partnership with Eli Lilly's Lilly TuneLab. The deal involves providing antibody characterization data services for TuneLab's AI/ML drug discovery platform. According to Twist's CEO, the partnership aims to accelerate antibody drug discovery by combining experimental data with AI models.

Original reporting
investing.com
Published Sep 16, 2026, 5:55 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 6:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$TWST
Bullish
medium confidence
Mentioned
$TWST · $LLY
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$TWSTBullishMed
01

Why it matters

The deal positions Twist as a key data supplier for AI models, potentially expanding its addressable market.

02

Market read

A new commercial partnership that could enhance Twist's growth trajectory and influence biotech AI collaborations.

03

What to watch

Potential integration challenges and reliance on Eli Lilly's platform adoption rates.

Relevance 6/10Novelty 6/10Timing: Wednesday

Background

Twist Bioscience provides high‑throughput DNA synthesis and antibody characterization services; Eli Lilly launched TuneLab to accelerate AI‑driven drug discovery.

Company-level read

Ticker impact

$TWSTBullishMedium confidence
Context

Twist Bioscience announced a new partnership with Eli Lilly's TuneLab AI/ML platform, driving a 3% share rise.

Expected impact

Potential upside of 5-8% over the next weeks if the collaboration gains traction.

Evidence & confidence

First‑report partnership, modest scale but clear commercial relevance; market already reacted positively.

Market effects

Sector

Strengthens the biotech AI/ML service niche and may prompt competitors to seek similar deals.

Regional

U.S. biotech sector sees modest uplift; limited effect on broader market.

Global

Highlights growing collaboration between pharma giants and specialized biotech firms.

Counterpoint

What could challenge this read

The partnership may be limited in scope and revenue, offering minimal long‑term upside.

Key entities

  • Company
    Twist Bioscience Corp

    NASDAQ‑listed biotech firm specializing in DNA synthesis and antibody services.

  • Company
    Eli Lilly and Company

    Pharmaceutical giant operating the TuneLab AI/ML platform.

Read at source← All news

Also covered by

4 outlets

Related articles

SEP 17
$TWSTHighAI 8/10

Twist Bioscience Stock Jumps As Lilly AI Deal Lifts Outlook

Twist Bioscience (TWST) stock rose 9.94% after announcing a deal with Eli Lilly to supply data for its AI/ML TuneLab platform. The company reported Q3 FY26 revenue of $118.4M, up 23% YoY, and raised full-year guidance to $456–457M. UBS initiated coverage with a Neutral rating and $144 price target. TWST is targeting adjusted EBITDA breakeven in Q4 FY26.

timothysykes.com3 min
SEP 17
$TWSTMedAI 8/10

Twist Bioscience Stock Jumps As Lilly AI Deal Fuels Growth Story

Twist Bioscience (TWST) stock rose 9.94% after reporting Q3 FY26 revenue of $118.4M, up 23% YoY, and raising full-year guidance to $456–$457M. The company announced an AI collaboration with Eli Lilly, boosting its valuation. TWST has 14 consecutive quarters of growth, 52.8% gross margin, and targets adjusted EBITDA breakeven in Q4 FY26.

stockstotrade.com3 min
SEP 17
$TWSTHighAI 8/10

Twist Bioscience TWST Stock Jumps On Lilly AI Deal

Twist Bioscience (TWST) stock rose 11.43% after announcing a deal with Eli Lilly to provide antibody characterization data for Lilly's AI/ML TuneLab platform. The company reported Q3 FY26 revenue of $118.4M, up 23% YoY, and raised full-year revenue guidance to $456–457M. UBS initiated coverage with a Neutral rating and a $144 price target.

timothysykes.com2 min
SEP 17
$LLYMedAI 8/10

QurCan Therapeutics Enters Strategic Research and Collaboration Agreement with Lilly to Advance Nucleic Acid Therapies for Central and Peripheral Nervous System Diseases

QurCan Therapeutics and Eli Lilly have entered a research and collaboration agreement to develop nucleic acid therapies for central and peripheral nervous system diseases. Lilly will invest strategically in QurCan, which could receive up to $237 million per program in milestones and royalties. QurCan will optimize therapeutics using its TERP platform, while Lilly will handle further research, clinical development, and commercialization.

antaranews.com2 min